Dr. Reddy’s Q1 FY23 Financial Results - Form 6-K

Dr. Reddy's Q1 FY23 Financial Results

Hyderabad, India, July 28, 2022: Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2022. The information mentioned in this release is on the basis of consolidated financial statements under International Financial Reporting Standards (IFRS).

Revenues	Rs. 5,215 Cr
	[Up: 6% YoY; Down: 4% QoQ]
Gross Margin	49.9%
	[Q1 FY22: 52.2%; Q4 FY22: 52.9%]
SG&A Expenses	Rs. 1,549 Cr
	[Up: 3% YoY; Down: 1% QoQ]
R&D Expenses	Rs. 433 Cr
	[8.3% of Revenues]
EBITDA	Rs. 1,779 Cr
	[34.1% of Revenues]
Profit before Tax	Rs. 1,466 Cr
	[Up: 97% YoY; Up: 490% QoQ]
Profit after Tax	Rs. 1,188 Cr
	[Up: 108% YoY; Up: 1,257% QoQ]

Commenting on the results, Co-Chairman & MD, G V Prasad said "Our underlying business revenues adjusted for covid products contribution during last year have grown well. The profits were aided by a few non-recurring incomes, offsetting the near term headwinds. We continue to improve the health of our core businesses through productivity improvement and robust product pipelines".

All amounts in millions, except EPS

All US dollar amounts based on convenience translation rate of I USD = Rs. 79.02

Dr. Reddy's Laboratories Limited and Subsidiaries

Consolidated Income Statement

		Q1 FY23			Q1 FY22			YoY			Q4 FY22			QoQ
Particulars		($)			(Rs.)			($)			(Rs.)			Gr %			($)			(Rs.)			Gr%
Revenues			660				52,154				623				49,194				6				688				54,368				(4	)
Cost of Revenues			331				26,148				297				23,495				11				324				25,625				2
Gross Profit			329				26,006				325				25,699				1				364				28,743				(10	)
Operating Expenses
Selling, General & Administrative expenses			196				15,493				190				15,045				3				198				15,674				(1	)
Research and Development expenses			55				4,325				57				4,534				(5	)			55				4,326				(0	)
Impairment of non-current assets			-				-				-				-								95				7,515				(100	)
Other operating income			(76	)			(6,024	)			(6	)			(487	)			1,137				(4	)			(291	)			1,970
Results from operating activities			155				12,212				84				6,607				85				19				1,519				704
Net finance income			(30	)			(2,349	)			(8	)			(652	)			260				(11	)			(859	)			173
Share of profit of equity accounted investees			(1	)			(94	)			(2	)			(166	)			(43	)			(1	)			(105	)			(10	)
Profit before income tax			185				14,655				94				7,425				97				31				2,483				490
Income tax expense			35				2,779				22				1,717				62				20				1,608				73
Profit for the period			150				11,876				72				5,708				108				11				875				1,257
Diluted Earnings Per Share (EPS)			0.90				71.40				0.43				34.34				109				0.07				5.26				1,261

As % to revenues		Q1 FY23			Q1 FY22			Q4 FY22
Gross Profit			49.9				52.2				52.9
SG&A			29.7				30.6				28.8
R&D			8.3				9.2				8.0
EBITDA			34.1				20.7				23.9
PBT			28.1				15.1				4.6
PAT			22.8				11.6				1.6

EBITDA Computation

		Q1 FY23			Q1 FY22			Q4 FY22
Particulars		($)			(Rs.)			($)			(Rs.)			($)			(Rs.)
Profit before Income Tax			185				14,655				94				7,425				31				2,483
Interest (income) / expense (net)*			1				84				(2	)			(142	)			0				24
Depreciation			26				2,050				25				1,973				26				2,039
Amortization			13				1,000				12				932				12				920
Impairment			-				-				-				-				95				7,515
EBITDA			225				17,789				129				10,188				164				12,980

* Includes income from Investments

All amounts in millions, except EPS

All US dollar amounts based on convenience translation rate of I USD = Rs. 79.02

Key Balance Sheet Items

		As on 30th Jun 2022			As on 31st Mar 2022			As on 30th Jun 2021
Particulars		($)			(Rs.)			($)			(Rs.)			($)			(Rs.)
Cash and cash equivalents and other investments			449				35,467				608				48,033				435				34,356
Trade receivables			927				73,274				846				66,818				774				61,148
Inventories			656				51,810				644				50,884				643				50,771
Property, plant and equipment			808				63,826				787				62,169				742				58,636
Goodwill and Other Intangible assets			458				36,213				401				31,664				503				39,746
Loans and borrowings (current & non-current)			312				24,666				428				33,845				422				33,373
Trade payables			317				25,052				324				25,572				362				28,607
Equity			2,531				2,00,039				2,411				1,90,527				2,254				1,78,114

Revenue Mix by Segment

		Q1 FY23			Q1 FY22			YoY			Q4 FY22			QoQ
Segment		(Rs.)			(Rs.)			Gr %			(Rs.)			Gr %
Global Generics			44,324				41,113				8				46,118				(4	)
North America			17,815				17,390				2				19,971				(11	)
Europe			4,141				3,994				4				4,444				(7	)
India			13,339				10,600				26				9,689				38
Emerging Markets			9,028				9,129				(1	)			12,013				(25	)
Pharmaceutical Services and Active Ingredients (PSAI)			7,090				7,540				(6	)			7,557				(6	)
Others			740				541				37				693				7
Total			52,154				49,194				6				54,368				(4	)

Revenue Analysis

Global Generics (GG)

Revenues from GG segment at Rs. 44.3 billion:

Ø	Year-on-year growth of 8% was driven by new product launches across most of our businesses and divestment of a few non-core brands in India, partly offset by price erosion in our generic markets, and higher base due to covid product sales in previous year.

Ø	Sequential decline of 4% was due to sales decline in North America (incremental competition on key products and price erosion) and Emerging Markets (normalization of channel inventory in Russia). This was partly offset by new product launches.

North America

Revenues from North America at Rs. 17.8 billion:

Ø	Year-on-year growth of 2%, driven by launch of new products and favorable forex rates, which was offset by price erosion in some of our key molecules.

Ø	Sequential decline of 11% was primarily on account of price erosion and decline in volumes for few products due to incremental competition.

Ø	During this quarter, we launched 7 new products. This includes launch of Ketorolac, OTC Nicotine Lozenges Original, Methylprednisolone Sodium Succinate, Pemetrexed Injection, Posaconazole Tabs and Sorafenib in the US and Pemetrexed Inj. in Canada.

Ø	We filed three ANDAs during the quarter. As of 30th June 2022, cumulatively 86 generic filings are pending for approval with the USFDA (83 ANDAs and 3 NDAs under 505(b)(2) route). Out of these 86 pending filings, 44 are Para IVs and we believe 24 have 'First to File' status.

Europe

Revenues from Europe at Rs. 4.1 billion:

Ø	Year-on-year growth of 4%, driven by launch of new products and scale up of base business, which was partly offset by price erosion in some molecules and adverse forex rates during the quarter.

Ø	Sequential decline of 7% was primarily on account of price erosion and adverse forex rates, which was partly offset by volume traction in base business.

India

Revenues from India at Rs. 13.3 billion:

Ø

Year-on-year growth of 26% was driven by divestment of a few non-core brands, revenue contribution from the products acquired / in-licensed from Novartis, growth in base business and new products contribution. The growth was partially offset due to covid product sales in Q1 FY22 which was not there in the current quarter.

Ø	Sequential growth of 38% was primarily driven by divestment of a few non-core brands, revenue contribution from the products acquired / in-licensed from Novartis, new products contribution and growth in base business.

Ø	We launched five new products during the quarter.

Emerging Markets

Revenues from Emerging Markets at Rs. 9.0 billion. Year-on-year decline of 1% and sequential decline of 25%:

Ø

Revenues for Russia at Rs. 3.2 billion. Year-on-year decline of 9% is primarily due to channel inventory normalization post stocking up in Q4 FY22, which was partly offset with launch of new products. Sequential decline of 53% was due to higher base in Q4 FY22 from brand divestment income and channel inventory normalization in the current quarter.

Ø	Revenues from other CIS countries and Romania at Rs. 1.9 billion. Year-on-year growth of 33% driven by volume traction in base business, favorable price benefits in some of our products and launch of new products. Sequential decline of 16% was primarily on account of reduction in volumes.

Ø

Revenues from Rest of World (RoW) territories at Rs. 3.9 billion. Year-on-year decline of 6% primarily on account of higher base in Q1 FY22 due to covid product sales and price decline in current quarter, partly offset by new product launches. Sequential growth of 36% was largely attributable to volume traction in our base business, price benefits in some of our markets and launch of new products.

Pharmaceutical Services and Active Ingredients (PSAI)

Revenues from PSAI at Rs. 7.1 billion. Year-on-year and sequential decline of 6% each.

Ø	Year-on-year decline was primarily on account of higher base in Q1 FY22 with covid product sales, partly offset by new products launched and favorable forex rates.

Ø	Sequential decline was primarily due to lower volumes of base business, partly offset by new product launches.

Income Statement Highlights:

Ø	Gross profit margin at 49.9%:

-	Decreased by ~230 bps over previous year and by ~300 bps sequentially, primarily on account of higher commodity prices, adverse leverage on manufacturing overheads, price erosion and forex related impact, which was partially benefited from brand divestment income.

-	Gross profit margin for GG and PSAI business segments are at 55.0% and 15.7% respectively.

Ø

Selling, general & administrative (SG&A) expenses at Rs. 15.5 billion, increased by 3% on a year-on-year basis and declined by 1% sequentially. Year-on-year increase was primarily attributable to investments being done towards marketing of some of our key brands, investments in digitalization and annual increments, which was partially offset with lower legal and professional expenses. On sequential basis, the expenses have been largely flat.

Ø	Research & development (R&D) expenses at Rs. 4.3 billion. As % to revenues - Q1 FY23: 8.3% | Q4 FY22: 8.0% | Q1 FY22: 9.2%. Our focus continues on building a global pipeline of products across our markets.

Ø

Other operating income at Rs. 6.0 billion compared to Rs. 0.5 billion in Q1 FY22. The increase was mainly on account of recognition of income from settlement agreement, with Indivior Inc., Indivior UK Limited and Aquestive Therapeutics, Inc., resolving all claims between the parties relating to the generic buprenorphine and naloxone sublingual film.

Ø	Net Finance income at Rs. 2.3 billion compared to Rs. 0.7 billion in Q1 FY22. The increase was primarily on account of foreign exchange gains due to favorable ruble rates.

Ø	Profit before Tax at Rs. 14.7 billion, increased by 97% year-on-year and increased by 490% sequentially.

Ø	Profit after Tax at Rs. 11.9 billion. The effective tax rate is 19.0% for the quarter.

Ø	Diluted earnings per share is at Rs. 71.40.

Other Highlights:

Ø	EBITDA is at Rs. 17.8 billion and the EBITDA margin is 34.1%.

Ø	Capital expenditure is at Rs. 3.3 billion.

Ø	Free cash-flow is a net outflow of Rs. 2.3 billion.

Ø	Net cash surplus for the company is at Rs. 12.8 billion as on June 30, 2022. Consequently, net debt to equity ratio is (0.06).

Earnings Call Details (06:30 pm IST, 09:00 am EDT, July 28, 2022)

The management of the Company will host an earnings call to discuss the Company's financial performance and answer any questions from the participants.

Conference Joining Information

Option 1: Express Join with DiamondPass™

Pre-register with the below link and join without waiting for the operator.

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=3962534&linkSecurityString=119134f0e6

Option 2: Join through below Dial-In Numbers
Universal Access Number:	+91 22 6280 1219 +91 22 7115 8120
International Toll Free Number:	USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448

No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.

Play Back: The play back will be available after the earnings call, till August 3^rd, 2022. For play back dial in phone No: +91 22 7194 5757 | +91 22 6663 5757, and Playback Code is 96436.

Transcript: Transcript of the Earnings call will be available on the Company's website: www.drreddys.com

About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its businesses, Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's operates in markets across the globe. Our Major markets include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein."

Public link

Please use the above public link if you want to share this noodl on another website.